|
15 |
Alteogen CEO Interview Featured in Scrip Citeline |
Alteogen |
2026-01-06 |
|
14 |
Alteogen to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Alteogen |
2025-12-10 |
|
13 |
Alteogen Selects Lead Underwriter for KOSPI Transfer Listing |
Alteogen |
2025-09-29 |
|
12 |
Alteogen Files PCT Patent Application for ADC Subcutaneous Formulation Technology |
Alteogen |
2025-09-26 |
|
11 |
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) |
Alteogen |
2025-09-17 |
|
10 |
Alteogen's CEO Soon Jae Park Interview Article (The Korea Economic Daily) |
Alteogen |
2025-08-19 |
|
9 |
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, ‘EYLUXVI® (ALT-L9)’ |
Alteogen |
2025-07-28 |
|
8 |
Alteogen Signs License Agreement with AstraZeneca for Subcutaneous Oncology Therapy Development |
Alteogen |
2025-03-17 |
|
7 |
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme Platform |
Alteogen |
2024-11-14 |
|
6 |
Alteogen Announces Amendment to License Agreement with MSD |
Alteogen |
2024-02-22 |
